UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?

A routine regulatory filing on Investegate on Tuesday quietly revealed something worth a closer look: BioPharma Credit PLC (BPCP), the London-listed specialty pharma lending fund, has expanded its loan exposure to UroGen Pharma (Nasdaq: URGN).

What happened

According to the BioPharma Credit announcement, the fund’s allocation in UroGen’s senior secured loan facility increased to $125M as part of a broader refinancing deal closed on February 26. The full facility — managed by Pharmakon Advisors — was doubled from $125M to $250M, with a first tranche of $200M funded at closing to refinance the existing loan and provide additional non-dilutive capital, and a second tranche of $50M available at UroGen’s discretion through June 2027. The fixed interest rate stays at 8.25%. BioPharma Credit also received $3M in make-whole and prepayment fees from the restructuring, as noted in the Investegate filing.

Why UroGen needed the money — and why lenders gave it

UroGen reported a net loss of $153.5M for 2025, with cash and marketable securities of $120.5M at year-end. That’s a tight runway for a company simultaneously launching a new drug, running multiple Phase 3 trials, and expanding its salesforce.

The new drug in question is ZUSDURI — the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, approved in June 2025. Net sales in 2025 were $15.8M, reflecting the initial launch period ahead of the permanent J Code. That J Code — the reimbursement key that unlocks buy-and-bill adoption in hospitals and urology practices — became effective January 1, 2026, and management says early signals are encouraging.

Management is targeting over $1 billion in potential peak revenue for ZUSDURI under an accelerated adoption scenario. That’s the number that explains why BioPharma Credit doubled its bet.

The JELMYTO backbone holds

Lenders don’t extend $250M to a company running on fumes and hope alone. The collateral here is real: JELMYTO generated net product revenue of $94M in 2025, with 7% year-over-year underlying demand growth. For 2026, UroGen guided JELMYTO revenue of $97M–$101M. That’s a steady, cash-generating anchor product that makes the ZUSDURI launch bet financeable.

The investor angle

For BioPharma Credit shareholders, this is straightforward yield-seeking in a secured position — 8.25% fixed against a company with a marketed product generating ~$100M annually and a potential blockbuster in early launch. Principal repayment doesn’t begin until Q1 2030, giving UroGen maximum runway to prove ZUSDURI’s commercial potential before debt service kicks in.

The risk? UroGen’s 2026 operating expenses are guided at $240M–$250M against revenues that won’t cover that for some time. If ZUSDURI adoption stalls — say, due to reimbursement friction or competitive pressure — the refinancing runway gets shorter fast.

For now, BioPharma Credit took a larger piece and pocketed a fee. The bet is on bladder cancer becoming a $1B franchise. 2026 will be the first real test.